-
公开(公告)号：CA2892045A1
公开(公告)日：2014-05-30
申请号：CA2892045
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC , PTC THERAPEUTICS INC
Inventor： LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D471/04
Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
-
公开(公告)号：WO2014081906A3
公开(公告)日：2014-07-17
申请号：PCT/US2013071132
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D239/48
CPC classification number: C07D403/12 , A61K31/506 , A61K45/06 , A61N5/10 , C07D403/04 , C07D471/04 , C07D487/04
Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
Abstract translation: 胺取代的反向嘧啶化合物及其形式，其抑制B细胞特异性莫洛尼鼠白血病病毒整合位点1（Bmi-1）蛋白的功能和水平降低，以及用于抑制Bmi-1功能并降低其水平的方法 本文描述了用于治疗由Bmi-1介导的癌症的Bmi-1。
-
公开(公告)号：AU2018271277B2
公开(公告)日：2020-07-16
申请号：AU2018271277
申请日：2018-11-27
Applicant: PTC THERAPEUTICS INC
Inventor： DU WU , BAIAZITOV RAMIL , LEE CHANG-SUN , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D239/48
Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
-
公开(公告)号：HK1215032A1
公开(公告)日：2016-08-12
申请号：HK16103069
申请日：2016-03-16
Applicant: PTC THERAPEUTICS INC
Inventor： LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D20060101
-
公开(公告)号：PE20151413A1
公开(公告)日：2015-10-23
申请号：PE2015000665
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： DU WU , SYDORENKO NADIYA , BAIAZITOV RAMIL , REN HONGYU , DAVIS THOMAS W , PAGET STEVEN D , MOON YOUNG-CHOON , CAO LIANGXIAN , LEE CHANG-SUN , LIU RONGGANG , WILDE RICHARD
IPC: C07D239/48
Abstract: Referido a derivados de pirimidina sustituida con amina de formula (I) y formas de la misma que inhiben la funcion y reducen el nivel de la proteina del sitio de integracion 1 (Bmi-1) del virus de la leucemia de Moloney especifico de celulas B su uso para inhibir la funcion de Bmi-1 y reducir el nivel de Bmi-1 en el tratamiento de un cancer mediado por Bmi-1. Donde R1 es heteroarilo, etc; R2 es H, CN, etc; R3 es H, CN, etc. R4 es cicloalquilo, etc. Los compuestos preferidos son: N-(4-metoxifenil)-2-(2-metil-1H-bencimidazol-1-il)pirimidin-4-amina; N-(2,3-dihidro-1,4-benzodioxin-6-il)-2-(2-metilimidazo[1,2-a]piridin-3-il)pirimidin-4-amina; entre otros
-
Patent Agency Ranking
公开(公告)号：CA2922657C
公开(公告)日：2022-04-12
申请号：CA2922657
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： DU WU , BAIAZITOV RAMIL , LEE CHANG-SUN , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D403/04 , A61K31/506 , A61P35/00 , C07D401/04 , C07D413/04 , C07D471/04
Abstract: Amine substituted pyrimidine compounds, including compound of formula (I): (see formula I) and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1.
-
公开(公告)号：PL2922828T3
公开(公告)日：2020-12-28
申请号：PL13857326
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： PAGET STEVEN D , REN HONGYU , LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D403/12 , A61K31/506 , A61P35/00 , C07D403/04 , C07D471/04 , C07D487/04
-
公开(公告)号：MX2015006469A
公开(公告)日：2015-10-29
申请号：MX2015006469
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD , MOON YOUNG-CHOON
IPC: C07D239/48
Abstract: Compuestos inversos de pirimidina sustituidos con amina y formas de la misma que inhiben la función y reducen el nivel de la proteína del sitio de integración 1 (Bmi-1) del virus de la leucemia de Moloney específico de células B para su uso para inhibir la función de Bmi-1 y reducir el nivel de Bmi-1 para el tratamiento de un cáncer mediado por Bmi-1 se describen en el presente documento.
-
公开(公告)号：PE14132015A1
公开(公告)日：2015-10-23
申请号：PE0006652015
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： DU WU , SYDORENKO NADIYA , BAIAZITOV RAMIL , REN HONGYU , DAVIS THOMAS W , PAGET STEVEN D , MOON YOUNG-CHOON , CAO LIANGXIAN , LEE CHANG-SUN , LIU RONGGANG , WILDE RICHARD
IPC: C07D239/48
CPC classification number: C07D403/12 , A61K31/506 , A61K45/06 , A61N5/10 , C07D403/04 , C07D471/04 , C07D487/04 , Y02A50/411
Abstract: Referido a derivados de pirimidina sustituida con amina de formula (I) y formas de la misma que inhiben la funcion y reducen el nivel de la proteina del sitio de integracion 1 (Bmi-1) del virus de la leucemia de Moloney especifico de celulas B su uso para inhibir la funcion de Bmi-1 y reducir el nivel de Bmi-1 en el tratamiento de un cancer mediado por Bmi-1. Donde R1 es heteroarilo, etc; R2 es H, CN, etc; R3 es H, CN, etc. R4 es cicloalquilo, etc. Los compuestos preferidos son: N-(4-metoxifenil)-2-(2-metil-1H-bencimidazol-1-il)pirimidin-4-amina; N-(2,3-dihidro-1,4-benzodioxin-6-il)-2-(2-metilimidazo[1,2-a]piridin-3-il)pirimidin-4-amina; entre otros
-
公开(公告)号：SG11201503982XA
公开(公告)日：2015-06-29
申请号：SG11201503982X
申请日：2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor： LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D239/48
Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.023 seconds)
